Octreotide acetate successfully treated a bowel obstruction caused by peritoneally disseminated gastric cancer, thereby enabling the subsequent use of oral S-1 chemotherapy

Koshi Kumagai, Yoshiro Saikawa, Kazumasa Fukuda, Ryo Ito, Takahiro Igarashi, Shinichi Tsuwano, Rieko Nakamura, Tsunehiro Takahashi, Hiroya Takeuchi, Yuukou Kitagawa

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

A 68-year-old woman presented with severe bowel obstruction and was subsequently diagnosed with stage IV gastric cancer with peritoneal dissemination. She was immediately stabilized in the hospital with the placement of a nasointestinal tube. Abdominal computed tomography showed multiple intraperitoneal nodules consistent with peritoneal dissemination of the gastric cancer. The patient's inability to tolerate oral intake was a contraindication to using S-1 chemotherapy, currently one of the most effective medications used for gastric cancer in Japan. Therefore, she was initially treated with octreotide acetate (OA). Her bowel obstruction was sufficiently attenuated on the seventh day after the initiation of treatment with OA to permit the initiation of oral S-1, along with low-dose cisplatin (CDDP) and radiation. S-1 was orally administered at a dose of 100 mg/day per body (80 mg/m2 per day) on days 1-28, and CDDP was infused at a dose of 7.8 mg/day per body (6 mg/m2 per day) on days 1-5, 8-12, and 15-19. Radiation therapy (2 Gy/day for 5 days/week) was performed with the chemotherapy. Despite no change being shown on her imaging findings with the chemotherapy, the patient's bowel obstruction resolved and she was able to tolerate both liquids and solid food orally. She was discharged 2 months after admission. Seven months after beginning the chemotherapy, she was still doing well on outpatient chemotherapy with S-1 and CDDP, and had no decline in her quality of life or progression of her disease.

Original languageEnglish
Pages (from-to)372-375
Number of pages4
JournalInternational Journal of Clinical Oncology
Volume14
Issue number4
DOIs
Publication statusPublished - 2009 Aug

Fingerprint

Octreotide
Stomach Neoplasms
Drug Therapy
Cisplatin
Disease Progression
Japan
Outpatients
Radiotherapy
Tomography
Quality of Life
Radiation
Food

Keywords

  • Chemoradiotherapy
  • Gastric cancer
  • Malignant bowel obstruction
  • Octreotide acetate
  • S-1

ASJC Scopus subject areas

  • Oncology
  • Surgery
  • Hematology

Cite this

Octreotide acetate successfully treated a bowel obstruction caused by peritoneally disseminated gastric cancer, thereby enabling the subsequent use of oral S-1 chemotherapy. / Kumagai, Koshi; Saikawa, Yoshiro; Fukuda, Kazumasa; Ito, Ryo; Igarashi, Takahiro; Tsuwano, Shinichi; Nakamura, Rieko; Takahashi, Tsunehiro; Takeuchi, Hiroya; Kitagawa, Yuukou.

In: International Journal of Clinical Oncology, Vol. 14, No. 4, 08.2009, p. 372-375.

Research output: Contribution to journalArticle

Kumagai, Koshi ; Saikawa, Yoshiro ; Fukuda, Kazumasa ; Ito, Ryo ; Igarashi, Takahiro ; Tsuwano, Shinichi ; Nakamura, Rieko ; Takahashi, Tsunehiro ; Takeuchi, Hiroya ; Kitagawa, Yuukou. / Octreotide acetate successfully treated a bowel obstruction caused by peritoneally disseminated gastric cancer, thereby enabling the subsequent use of oral S-1 chemotherapy. In: International Journal of Clinical Oncology. 2009 ; Vol. 14, No. 4. pp. 372-375.
@article{afaaf9ed8b254929986c8d3b3d0d17ed,
title = "Octreotide acetate successfully treated a bowel obstruction caused by peritoneally disseminated gastric cancer, thereby enabling the subsequent use of oral S-1 chemotherapy",
abstract = "A 68-year-old woman presented with severe bowel obstruction and was subsequently diagnosed with stage IV gastric cancer with peritoneal dissemination. She was immediately stabilized in the hospital with the placement of a nasointestinal tube. Abdominal computed tomography showed multiple intraperitoneal nodules consistent with peritoneal dissemination of the gastric cancer. The patient's inability to tolerate oral intake was a contraindication to using S-1 chemotherapy, currently one of the most effective medications used for gastric cancer in Japan. Therefore, she was initially treated with octreotide acetate (OA). Her bowel obstruction was sufficiently attenuated on the seventh day after the initiation of treatment with OA to permit the initiation of oral S-1, along with low-dose cisplatin (CDDP) and radiation. S-1 was orally administered at a dose of 100 mg/day per body (80 mg/m2 per day) on days 1-28, and CDDP was infused at a dose of 7.8 mg/day per body (6 mg/m2 per day) on days 1-5, 8-12, and 15-19. Radiation therapy (2 Gy/day for 5 days/week) was performed with the chemotherapy. Despite no change being shown on her imaging findings with the chemotherapy, the patient's bowel obstruction resolved and she was able to tolerate both liquids and solid food orally. She was discharged 2 months after admission. Seven months after beginning the chemotherapy, she was still doing well on outpatient chemotherapy with S-1 and CDDP, and had no decline in her quality of life or progression of her disease.",
keywords = "Chemoradiotherapy, Gastric cancer, Malignant bowel obstruction, Octreotide acetate, S-1",
author = "Koshi Kumagai and Yoshiro Saikawa and Kazumasa Fukuda and Ryo Ito and Takahiro Igarashi and Shinichi Tsuwano and Rieko Nakamura and Tsunehiro Takahashi and Hiroya Takeuchi and Yuukou Kitagawa",
year = "2009",
month = "8",
doi = "10.1007/s10147-008-0886-8",
language = "English",
volume = "14",
pages = "372--375",
journal = "International Journal of Clinical Oncology",
issn = "1341-9625",
publisher = "Springer Japan",
number = "4",

}

TY - JOUR

T1 - Octreotide acetate successfully treated a bowel obstruction caused by peritoneally disseminated gastric cancer, thereby enabling the subsequent use of oral S-1 chemotherapy

AU - Kumagai, Koshi

AU - Saikawa, Yoshiro

AU - Fukuda, Kazumasa

AU - Ito, Ryo

AU - Igarashi, Takahiro

AU - Tsuwano, Shinichi

AU - Nakamura, Rieko

AU - Takahashi, Tsunehiro

AU - Takeuchi, Hiroya

AU - Kitagawa, Yuukou

PY - 2009/8

Y1 - 2009/8

N2 - A 68-year-old woman presented with severe bowel obstruction and was subsequently diagnosed with stage IV gastric cancer with peritoneal dissemination. She was immediately stabilized in the hospital with the placement of a nasointestinal tube. Abdominal computed tomography showed multiple intraperitoneal nodules consistent with peritoneal dissemination of the gastric cancer. The patient's inability to tolerate oral intake was a contraindication to using S-1 chemotherapy, currently one of the most effective medications used for gastric cancer in Japan. Therefore, she was initially treated with octreotide acetate (OA). Her bowel obstruction was sufficiently attenuated on the seventh day after the initiation of treatment with OA to permit the initiation of oral S-1, along with low-dose cisplatin (CDDP) and radiation. S-1 was orally administered at a dose of 100 mg/day per body (80 mg/m2 per day) on days 1-28, and CDDP was infused at a dose of 7.8 mg/day per body (6 mg/m2 per day) on days 1-5, 8-12, and 15-19. Radiation therapy (2 Gy/day for 5 days/week) was performed with the chemotherapy. Despite no change being shown on her imaging findings with the chemotherapy, the patient's bowel obstruction resolved and she was able to tolerate both liquids and solid food orally. She was discharged 2 months after admission. Seven months after beginning the chemotherapy, she was still doing well on outpatient chemotherapy with S-1 and CDDP, and had no decline in her quality of life or progression of her disease.

AB - A 68-year-old woman presented with severe bowel obstruction and was subsequently diagnosed with stage IV gastric cancer with peritoneal dissemination. She was immediately stabilized in the hospital with the placement of a nasointestinal tube. Abdominal computed tomography showed multiple intraperitoneal nodules consistent with peritoneal dissemination of the gastric cancer. The patient's inability to tolerate oral intake was a contraindication to using S-1 chemotherapy, currently one of the most effective medications used for gastric cancer in Japan. Therefore, she was initially treated with octreotide acetate (OA). Her bowel obstruction was sufficiently attenuated on the seventh day after the initiation of treatment with OA to permit the initiation of oral S-1, along with low-dose cisplatin (CDDP) and radiation. S-1 was orally administered at a dose of 100 mg/day per body (80 mg/m2 per day) on days 1-28, and CDDP was infused at a dose of 7.8 mg/day per body (6 mg/m2 per day) on days 1-5, 8-12, and 15-19. Radiation therapy (2 Gy/day for 5 days/week) was performed with the chemotherapy. Despite no change being shown on her imaging findings with the chemotherapy, the patient's bowel obstruction resolved and she was able to tolerate both liquids and solid food orally. She was discharged 2 months after admission. Seven months after beginning the chemotherapy, she was still doing well on outpatient chemotherapy with S-1 and CDDP, and had no decline in her quality of life or progression of her disease.

KW - Chemoradiotherapy

KW - Gastric cancer

KW - Malignant bowel obstruction

KW - Octreotide acetate

KW - S-1

UR - http://www.scopus.com/inward/record.url?scp=69249198072&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69249198072&partnerID=8YFLogxK

U2 - 10.1007/s10147-008-0886-8

DO - 10.1007/s10147-008-0886-8

M3 - Article

C2 - 19705252

AN - SCOPUS:69249198072

VL - 14

SP - 372

EP - 375

JO - International Journal of Clinical Oncology

JF - International Journal of Clinical Oncology

SN - 1341-9625

IS - 4

ER -